Title:
An Open Label Phase II Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1 (AHEAD-MERIT)
Phase:
II
Contact:
Marina Fierhauser / Study Nurse
Email-Address:
Marina.Fierhauser@med.uni-heidelberg.de
Clinical Investigator:
Prof. Dr. Jürgen Krauss
Registration:
Die Studie ist bei den U.S. National Institutes of Health(ClinicalTrials.gov) registriert. Siehe
NCT04534205
EudraCT-Number:
(siehe EU klinisches Studienregister)
2020-001400-41